drospirenone
Jump to navigation
Jump to search
Introduction
Progestational agent. Used in combination oral contraceptive Yasmin.
Adverse effects
- hyperkalemia[1][2]
- risk of venous thromboembolism greater for oral contraceptives containing drospirenone vs levonorgestrel (OR=2.4-3.3)[3][4]
Mechanism of action
- progestational agent
- antimineralocortocoid activity
- antiandrogenic activity
More general terms
Additional terms
Component of
- drospirenone/ethinyl estradiol/metafolin
- drospirenone/estradiol/ethinyl estradiol
- Yaz
- Angeliq (drospirenone, estradiol)
- drospirenone/estradiol
- drospirenone/ethinyl estradiol
References
- ↑ 1.0 1.1 Prescriber's Letter 8(6):34 2001
- ↑ 2.0 2.1 Prescriber's Letter 16(10): 2009 Safety of Drospirenone-Containing Oral Contraceptives Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=251007&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ 3.0 3.1 Jick SS and Hernandez RK Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case- control study using United States claims data BMJ 2011; 342:d2151 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21511805 <Internet> http://www.bmj.com/content/342/bmj.d2151
Parkin L et al Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database BMJ 2011; 342:d2139 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21511804 <Internet> http://www.bmj.com/content/342/bmj.d2139
Dunn N The risk of deep venous thrombosis with oral contraceptives containing drospirenone BMJ 2011; 342:d2519 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21511807 <Internet> http://www.bmj.com/content/342/bmj.d2519.extract
FDA Safety Alert: Posted 05/31/2011 Birth Control Pills Containing Drospirenone: Possible Increased Risk of Blood Clots http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm257337.htm - ↑ 4.0 4.1 Prescriber's Letter 19(1): 2012 Safety of Drospirenone Contraceptives and the Contraceptive Patch Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=280103&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ FDA MedWatch: 04/10/2012 Birth Control Pills Containing Drospirenone: Label Change-Products may be associated with a higher risk for blood clots http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm299605.htm